Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.6%
- Check14 days agoChange DetectedDifference0.9%
- Check21 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a clinical study involving surufatinib and tislelizumab, while adding new information about various cancer types and collaborators.SummaryDifference32%
- Check29 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.4) and indicates that results have been submitted, replacing the previous status of no results posted.SummaryDifference1%
- Check36 days agoChange DetectedThe page has been updated to include information on Neuroendocrine Tumors while removing references to Small Cell Lung Cancer.SummaryDifference0.8%
- Check43 days agoChange DetectedThe page has been updated to include information on Neuroendocrine Tumors while removing references to Soft Tissue Sarcoma.SummaryDifference0.2%
Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.